Limits...
Clinical utility of valsartan in treatment of children and adolescents with high blood pressure.

Kaushik M, Mohiuddin SM - Adolesc Health Med Ther (2011)

Bottom Line: The need for better tolerated antihypertensives had led to development of many new antihypertensives.Otherwise, the drug has infrequent side effects.In summary, valsartan is a new and useful alternative to conventional antihypertensive therapy in pediatric population.

View Article: PubMed Central - PubMed

Affiliation: Division of Cardiology, Creighton University Medical Center, Omaha, NE, USA.

ABSTRACT
The incidence of hypertension in the pediatric population has been increasing secondary to lifestyle changes in children and adolescents. Recent studies have enhanced our understanding of the treatment of pediatric hypertension. Angiotensin-converting enzyme inhibitors have traditionally been the most commonly used class of medication in children with hypertension. This is partly due to the important role of the renin angiotensin aldosterone system pathway in the mediation of pediatric hypertension. Angiotensin receptor blockers provide a reasonable alternative to angiotensin-converting enzyme inhibitors. The need for better tolerated antihypertensives had led to development of many new antihypertensives. Valsartan is a relatively novel angiotensin receptor blocker that has been shown to be effective in the treatment of pediatric hypertension. Two recent trials have demonstrated the efficacy of valsartan monotherapy in the pediatric population aged 1-16 years. Once-daily oral preparations of valsartan achieve adequate blood pressure control in the pediatric population. Lack of generic formulations is an important disadvantage. Plasma levels are predictable and clearance is primarily by the liver. Valsartan should be prescribed cautiously for sexually active adolescent females due to concern about angiotensin receptor blocker fetopathy. Otherwise, the drug has infrequent side effects. In summary, valsartan is a new and useful alternative to conventional antihypertensive therapy in pediatric population.

No MeSH data available.


Related in: MedlinePlus

Use of common antihypertensives in major european countries.Note: Reprinted by permission from Macmillan Publishers Ltd: Journal of Human Hypertension. Balkrishnan R, Phatak H, Gleim G, Karve S. Assessment of the use of angiotensin receptor blockers in major european markets among paediatric population for treating essential hypertension. J Hum Hypertens. 2009;23:420–425. Copyright © 2009.11Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; FDC, fixed-dose combination; CCBs, calcium channel blockers; Comb, combination; EU, European Union.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3926775&req=5

f1-ahmt-2-097: Use of common antihypertensives in major european countries.Note: Reprinted by permission from Macmillan Publishers Ltd: Journal of Human Hypertension. Balkrishnan R, Phatak H, Gleim G, Karve S. Assessment of the use of angiotensin receptor blockers in major european markets among paediatric population for treating essential hypertension. J Hum Hypertens. 2009;23:420–425. Copyright © 2009.11Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; FDC, fixed-dose combination; CCBs, calcium channel blockers; Comb, combination; EU, European Union.

Mentions: Currently, multiple antihypertensive agents are approved for use in children (Table 1).10 A significant number of these medications have been approved since the passing of the Food and Drug Administration Modernization Act in the US in 1997 and other legislative changes and initiatives.10 Nevertheless, market trends suggest disproportionately more use of certain agents in the pediatric population. Even amongst the commonly used classes of drugs, angiotensin receptor blockers and angiotensin-converting enzyme inhibitors are more commonly prescribed classes compared with diuretics or beta-blockers in the pediatric population.11 Angiotensin receptor blockers as monotherapy or as fixed-dose combinations contributed to 26.3% of pediatric hypertension prescriptions in Europe11 (Figure 1). This trend indicates a significant physician and pediatrician preference for these agents independent of compelling indications. A low incidence of side effects with these medications may partly explain this preference.


Clinical utility of valsartan in treatment of children and adolescents with high blood pressure.

Kaushik M, Mohiuddin SM - Adolesc Health Med Ther (2011)

Use of common antihypertensives in major european countries.Note: Reprinted by permission from Macmillan Publishers Ltd: Journal of Human Hypertension. Balkrishnan R, Phatak H, Gleim G, Karve S. Assessment of the use of angiotensin receptor blockers in major european markets among paediatric population for treating essential hypertension. J Hum Hypertens. 2009;23:420–425. Copyright © 2009.11Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; FDC, fixed-dose combination; CCBs, calcium channel blockers; Comb, combination; EU, European Union.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3926775&req=5

f1-ahmt-2-097: Use of common antihypertensives in major european countries.Note: Reprinted by permission from Macmillan Publishers Ltd: Journal of Human Hypertension. Balkrishnan R, Phatak H, Gleim G, Karve S. Assessment of the use of angiotensin receptor blockers in major european markets among paediatric population for treating essential hypertension. J Hum Hypertens. 2009;23:420–425. Copyright © 2009.11Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; FDC, fixed-dose combination; CCBs, calcium channel blockers; Comb, combination; EU, European Union.
Mentions: Currently, multiple antihypertensive agents are approved for use in children (Table 1).10 A significant number of these medications have been approved since the passing of the Food and Drug Administration Modernization Act in the US in 1997 and other legislative changes and initiatives.10 Nevertheless, market trends suggest disproportionately more use of certain agents in the pediatric population. Even amongst the commonly used classes of drugs, angiotensin receptor blockers and angiotensin-converting enzyme inhibitors are more commonly prescribed classes compared with diuretics or beta-blockers in the pediatric population.11 Angiotensin receptor blockers as monotherapy or as fixed-dose combinations contributed to 26.3% of pediatric hypertension prescriptions in Europe11 (Figure 1). This trend indicates a significant physician and pediatrician preference for these agents independent of compelling indications. A low incidence of side effects with these medications may partly explain this preference.

Bottom Line: The need for better tolerated antihypertensives had led to development of many new antihypertensives.Otherwise, the drug has infrequent side effects.In summary, valsartan is a new and useful alternative to conventional antihypertensive therapy in pediatric population.

View Article: PubMed Central - PubMed

Affiliation: Division of Cardiology, Creighton University Medical Center, Omaha, NE, USA.

ABSTRACT
The incidence of hypertension in the pediatric population has been increasing secondary to lifestyle changes in children and adolescents. Recent studies have enhanced our understanding of the treatment of pediatric hypertension. Angiotensin-converting enzyme inhibitors have traditionally been the most commonly used class of medication in children with hypertension. This is partly due to the important role of the renin angiotensin aldosterone system pathway in the mediation of pediatric hypertension. Angiotensin receptor blockers provide a reasonable alternative to angiotensin-converting enzyme inhibitors. The need for better tolerated antihypertensives had led to development of many new antihypertensives. Valsartan is a relatively novel angiotensin receptor blocker that has been shown to be effective in the treatment of pediatric hypertension. Two recent trials have demonstrated the efficacy of valsartan monotherapy in the pediatric population aged 1-16 years. Once-daily oral preparations of valsartan achieve adequate blood pressure control in the pediatric population. Lack of generic formulations is an important disadvantage. Plasma levels are predictable and clearance is primarily by the liver. Valsartan should be prescribed cautiously for sexually active adolescent females due to concern about angiotensin receptor blocker fetopathy. Otherwise, the drug has infrequent side effects. In summary, valsartan is a new and useful alternative to conventional antihypertensive therapy in pediatric population.

No MeSH data available.


Related in: MedlinePlus